Friday, 23 November 2018

U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million

/ by  / in , / with No comments /

Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.


from Reuters: Top News https://ift.tt/2FDJnsa
//

Related Posts:

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)